Atum
Jun 02, 2017
Tesaro’s Zejula; Mylan on EpiPen; Ohio sues drugmakers; ATUM, Horizon Discovery Announce deal
Tesaro and its new med Zejula are on the block, but bidders aren't rushing in Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street Journal. That’s Tesaro, whose PARP inhibitor Zejula won FDA approval in March. That med ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
